Reuters logo
6 months ago
BRIEF-Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir
February 13, 2017 / 9:14 PM / 6 months ago

BRIEF-Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir

Feb 13 (Reuters) - Aviragen Therapeutics Inc

* Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir

* Aviragen Therapeutics Inc - SPIRITUS trial did not meet its primary endpoint

* Aviragen - Vapendavir did not demonstrate a statistically significant reduction in asthma control questionnaire-6 (ACQ-6) at day 14, primary endpoint

* Aviragen - secondary endpoints did not show significant differences between treatment groups and placebo

* Aviragen - Vapendavir was shown to be generally well tolerated and safety profile was consistent with previous clinical studies

* Aviragen - Vapendavir did not show a significant reduction in asthma control questionnaire-6 for either 264 mg or 528 mg cohorts compared to placebo Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below